Immunizations

HMSA Commercial plans cover immunizations in accordance with the recommendations of the Advisory Committee on Immunization Practices (ACIP).

ACIP Recommendations

The Advisory Committee on Immunization Practices (ACIP) develops vaccine recommendations for children and adults. The recommendations include the age(s) when the vaccine should be given, the number of doses needed, the amount of time between doses, and precautions and contraindications.

All of the ACIP’s recommendations are posted on the Centers of Disease Control and Prevention (CDC) webpage at: https://www.cdc.gov/vaccines/hcp/acip-recs/.

COVID-19 Vaccine and Vaccine Administration codes.

For commercial members, as of 09/12/2023, COVID-19 vaccines will be commercially available and covered by HMSA. Coverage is limited to the administration codes, see COVID-19 Immunization Administration codes.

See Additional billing information.

Vaccine Codes (Alphabetically ordered by Vaccine)
Code Long Description Vaccine
90589 Chikungunya virus vaccine, live attenuated, for intramuscular use Chikungunya
90593 Chikungunya virus vaccine, recombinant, for intramuscular use Chikungunya
90625 Cholera vaccine, live, adult dosage, 1 dose schedule, for oral use Cholera
90683 Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use Respiratory Syncytial Virus (RSV)
90690 Typhoid vaccine, live, oral Typhoid
91304 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanparticle, saponin-based adjuvant, 5 mcg/0.2 mL dosage, for intramuscular use COVID-19 vaccine - Novavax
91318 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 3 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use COVID-19 vaccine – Pfizer-BioNTech
91319 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 10 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
91320 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
91321 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use COVID-19 - Moderna
91322 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 50 mcg/0.5 mL dosage, for intramuscular use
91323 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 10 mcg/0.2 mL dosage, for intramuscular use
90584 Dengue vaccine, quadrivalent, live, 2 dose schedule, for subcutaneous use Dengue
90587 Dengue vaccine, quadrivalent, live, 3 dose schedule, for subcutaneous use
90696 Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine, when administered to children 4 through 6 years of age, for intramuscular use Diphtheria, Tetanus, Pertussis, Poliovirus
(DTaP-IPV)
90697 Diphtheria, tetanus toxoids, acellular pertussis vaccine, inactivated poliovirus vaccine, Haemophilus influenzae type b PRP-OMP conjugate vaccine, and hepatitis B vaccine, for intramuscular use Diphtheria, Tetanus, Pertussis, Poliovirus, Haemophilus Influenzae type B, and Hepatitis B
(DTaP-IPV-Hib-HepB)
90698 Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, for intramuscular use Diphtheria, Tetanus, Pertussis, Poliovirus, and Haemophilus influenzae type B
(DTaP-IPV/Hib)
90700 Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use Diphtheria, Tetanus, and Pertussis
(DTaP)
90702 Diphtheria and tetanus toxoids adsorbed when administered to individuals younger than 7 years, for intramuscular use Diphtheria and Tetanus
(DT)
90723 Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine, for intramuscular use Diphtheria, Tetanus, Pertussis , Hepatitis B, and Poliovirus
(DTaP-HepB-IPV)
90758 Zaire ebolavirus vaccine, live, for intramuscular use Ebolavirus
90647 Haemophilus influenzae type b vaccine, PRP-OMP conjugate, 3 dose schedule, for intramuscular use Haemophilus influenzae type b
(Hib)
90648 Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use
90632 Hepatitis A vaccine (HepA), adult dosage, for intramuscular use Hepatitis A
90633 Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use
90634 Hepatitis A vaccine (HepA), pediatric/adolescent dosage-3 dose schedule, for intramuscular use
90636 Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use Hepatitis A and Hepatitis B
90739 Hepatitis B vaccine (HepB), CpG-adjuvanted, adult dosage, 2 dose or 4 dose schedule, for intramuscular use Hepatitis B
90740 Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 3 dose schedule, for intramuscular use
90743 Hepatitis B vaccine (HepB), adolescent, 2 dose schedule, for intramuscular use
90744 Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use
90746 Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use
90747 Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 4 dose schedule, for intramuscular use
90759 Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use
90748 Hepatitis B and Haemophilus influenzae type b vaccine, for intramuscular use Hepatitis B and Haemophilus influenzae type b (Hib-HepB)
90649 Human Papillomavirus vaccine, types 6, 11, 16, 18, quadrivalent (4vHPV), 3 dose schedule, for intramuscular use Human Papillomavirus Virus
90650 Human Papillomavirus vaccine, types 16, 18, bivalent (2vHPV), 3 dose schedule, for intramuscular use
90651 Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use
90630 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use Influenza
90653 Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use
90654 Influenza virus vaccine, trivalent (IIV3), split virus, preservative-free, for intradermal use
90655 Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use
90656 Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use
90657 Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use
90658 Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use
90660 Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use
90661 Influenza virus vaccine, trivalent (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use
90662 Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use
90672 Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use
90673 Influenza virus vaccine, trivalent (RIV3), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use
90674 Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use
90682 Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use
90685 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL, for intramuscular use
90686 Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use
90687 Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use
90688 Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use
90689 Influenza virus vaccine, quadrivalent (IIV4), inactivated , adjuvanted, preservative, preservative free, 0.25 mL dosage, for intramuscular use
90694 Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intramuscular use
Q2034 Influenza virus vaccine, split virus, for intramuscular use (Agriflu)
Q2035 Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (AFLURIA)
Q2036 Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (FLULAVAL)
Q2037 Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (FLUVIRIN)
Q2038 Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (Fluzone)
90738 Japanese encephalitis virus vaccine, inactivated, for intramuscular use Japanese Encephalitis
90707 Measles, mumps and rubella virus vaccine, live, for subcutaneous use Measles, Mumps, Rubella
(MMR)
90710 Measles, mumps, rubella, and varicella vaccine, live, for subcutaneous use Measles, Mumps, Rubella and Varicella
(MMRV)
90623 Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y-tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Meningococcal
(MENACWY-TT MENB-FHBP)
90624 Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y-tetanus toxoid carrier, and Men B-FHbp, for intramuscular use Meningococcal
90619 Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier, for intramuscular use Meningococcal and Tetanus
(MENACWY-TT)
90620 Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B, 2 dose schedule, for intramuscular use Meningococcal
(MenB-4C)
90621 Meningococcal recombinant lipoprotein vaccine, serogroup B, 2 or 3 dose schedule, for intramuscular use Meningococcal
(MenB-FHbp)
90644 Meningococcal conjugate vaccine, serogroups C & Y and Haemophilus influenzae type B vaccine, 4 dose schedule, when administered to children 6 weeks-18 months of age, for intramuscular use Meningococcal and Haemophilus influenzae type B
(Hib-MENCY)
90733 Meningococcal polysaccharide vaccine serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier or CRM197 carrier, for intramuscular use Meningocococcal
Polysaccharide
(MPSV4)
90734 Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier or CRM197 carrier (MenACWY-CRM), for intramuscular use Meningococcal ACWY
Pneumococcal conjugate
(MENACWY-D)
90670 Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use Pneumococcal conjugate
90671 Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular use
90677 Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use
90684 Pneumococcal conjugate vaccine, 21 valent (PCV21), for intramuscular use
90732 Pneumococcal polysaccharide vaccine, 23-valent, adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use Pneumococcal polysaccharide
(PPSV23)
90713 Poliovirus vaccine, inactivated, for subcutaneous or intramuscular use Poliovirus
(IPV)
90380 Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use Respiratory Syncytial Virus (RSV)
90381 Respiratory syncytial virus, monoclonal antibody, seasonal dose; 1 mL dosage, for intramuscular use
90382 Respiratory syncytial virus, monoclonal antibody, seasonal dose, 0.7 mL, for intramuscular use
90678 Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use
90679 Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use
90680 Rotavirus vaccine, pentavalent, 3 dose schedule, live, for oral use Rotavirus
(RV5)
90681 Rotavirus vaccine, human, attenuated, 2 dose schedule, live, for oral use Rotavirus
(RV1)
90714 Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use Tetanus and diphtheria
(Td)
90715 Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use Tetanus, Diphtheria, and Pertussis
(Tdap)
90626 Tick-borne encephalitis virus vaccine, inactivated; 0.25 mL dosage, for intramuscular use Tick-borne encephalitis
90627 Tick-borne encephalitis virus vaccine, inactivated; 0.5 mL dosage, for intramuscular use
90691 Typhoid vaccine, Vi capsular polysaccharide, for intramuscular use Typhoid
(ViCPs)
90716 Varicella virus vaccine, live, for subcutaneous use Varicella
(VAR
90717 Yellow fever vaccine, live, for subcutaneous use Yellow fever
90736 Zoster (shingles) vaccine, live, for subcutaneous injection Zoster
(HZV)
90750 Zoster (shingles) vaccine, recombinant, subunit, adjuvanted, for intramuscular use
Vaccine Administration Codes
Code Long Description Used for
90460 Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered 0 through 18 years; first or only component of each vaccine or toxoid administered
90461 Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure) 0 through 18 years; each additional vaccine or toxoid component administered
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) 1 vaccine (single or combination vaccine/toxoid)
90472 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) Each additional vaccine (single or combination vaccine/toxoid)
90473 Immunization administration by intranasal or oral route; 1 vaccine (single or combination vaccine/toxoid) Administration by intranasal or oral route; 1 vaccine (single or combination vaccine/toxoid)
90474 Immunization administration by intranasal or oral route; each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) Administration by intranasal or oral route; each additional vaccine (single or combination vaccine/toxoid)
90480 Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose Covid-19 Administration code
(i.e. 91318, 91319, 91320, 91321, & 91322)
96380 Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection, with counseling by physician or other qualified health care professional Respiratory Syncytial Virus administration code
(i.e. used with 90380 or 90381)
96381 Administration of respiratory syncytial virus, monoclonal antibody, seasonal dose by intramuscular injection
G0008 Administration of influenza virus vaccine  
G0009 Administration of pneumococcal vaccine  
G0010 Administration of hepatitis B vaccine  

The original monovalent vaccines’ emergency use authorization (EUA) has been rescinded and those vaccines are no longer recommended for use, effective November 1, 2023

Deleted Codes as of November 1, 2023
COVID-19 Vaccine Codes COVID-19 Vaccine Administration Codes Manufacturer
91300 0001A (1st dose)
0002A (2nd dose)
0003A (3rd dose)
0004A (Booster)
Pfizer, Inc
91301 0011A (1st dose)
0012A (2nd dose)
0013A (3rd dose)
Moderna, Inc
91302 0021A (1st dose)
0022A (2nd dose)
Astra Zeneca, Plc
91303 0031A (1st dose)
0034A (2nd dose)
Janssen
91305 0051A (1st dose)
0052A (2nd dose)
0053A (3rd dose)
0054A (Booster)
Pfizer, Inc
91306 0064A (Booster) Moderna, Inc
91307 0071A (1st dose)
0072A (2nd dose)
0073A (3rd dose)
0074A (Booster)
Pfizer, Inc
91308 0081A (1st dose)
0082A (2nd dose)
0083A (3rd dose)
Pfizer, Inc
91309 0091A (1st dose)
0092A (2nd dose)
0093A (3rd dose)
0094A (Booster)
Moderna, Inc
91310 0104A (Booster) Sanofi Pasteur
91311 0111A (1st dose)
0112A (2nd dose)
0113A (3rd dose)
Moderna, Inc
91312 0121A (1st dose)
0124A (Additional dose)
Pfizer, Inc
91313 0134A (Additional dose) Moderna, Inc
91314 0141A (1st dose)
0142A (2nd dose)
0144A (Additional dose)
Moderna, Inc
91315 0151A (1st dose)
0154A (Additional dose)
Pfizer, Inc
91316 0164A (Additional dose) Moderna, Inc
91317 0171A (1st dose)
0172A (2nd dose)
0173A (3rd dose)
0174A (Additional dose)
Pfizer, Inc
N/A 0041A (1st dose)
0042A (2nd dose)
0044A (3rd dose)
Novavax, Inc

• Please be sure to use the most up-to-date industry-standard procedure, revenue, and diagnosis codes from the current CPT ®′′, HCPCS Level II, and ICD-10-CM manuals, as recommended by the American Medical Association (AMA), the Centers for Medicare & Medicaid Services (CMS), and the American Hospital Association.

♣Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently.

Claim Billing Examples• ♦

♦ CPT, diagnosis codes and ACIP recommendations are subject to change and are used as reference examples only.

EXAMPLE 1

ACIP Hepatitis B recommendation state “all adults requesting protection from HBV infection, without requiring them to acknowledge a specific factor” should be vaccinated.

Adult member presents to a physician office requesting the Hepatitis B vaccination. The adult member does not disclose a specific risk factor and is not required.

Diagnosis:

  • Z23 - Encounter for immunization

Code:

  • 90746 - Hepatitis B vaccine (HepB), adult dosage, 3 dose schedule, for intramuscular use
  • 90471 – Immunization Administration

Modifier:

  • No modifier necessary

EXAMPLE 2

ACIP Hepatitis A recommendation states “persons with end-stage renal disease, including predialysis, hemodialysis, peritoneal dialysis, and home dialysis patients” should be vaccinated.

Adult member presents to a physician office for Hepatitis A vaccine because the member is considered a high risk candidate due to End Stage Renal Disease.

Diagnosis:

  • N18.6 - End stage renal disease
  • Z99.2 - Dependence on renal dialysis
  • Z23 - Encounter for immunization

Code:

  • 90632 - Hepatitis A vaccine (HepA), adult dosage, for intramuscular use
    • Append modifier SK
  • 90471 – Immunization Administration

Modifier:

  • SK - Member of high risk population (use only with codes for immunization)

EXAMPLE 3

ACIP recommendation states, “pregnant people during 32 through 36 weeks gestation, using seasonal administration, to prevent RSV lower respiratory tract infection in infants” should be vaccinated. Member informs physician or other qualified healthcare professional provider that they are 33 weeks gestation.

Diagnosis:

  • Z23 - Encounter for immunization
  • Z3A.33 - 33 weeks gestation of pregnancy

Code:

  • 90678 – Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use
  • 90471 – Immunization Administration

Additional Billing Information• ♣ ♦

  • Bill the procedure code(s) representing the vaccine/toxoid and the appropriate administration code (s) on the same claim.
  • HMSA prefers that a provider bills administration codes on a single line with a count (# of units).
  • HMSA does not pay for vaccines provided by the State.Vaccines provided by the state should append modifier SL (State supplied vaccine) on the vaccine claim line with a nominal bill charge of $0.00. Note: IF system is limited and a charge is required, bill charge at $0.01.
  • We encourage billing the COVID -19 vaccine & vaccine administration separately from other services rendered in the same visit.
  • During the public health emergency (PHE) period, COVID-19 vaccines are funded by the federal government. Therefore, you are not required to bill for the COVID-19 vaccines (CPT 91300, 91301, or 91303).
  • According to Noridian, UB claims billed for COVID-19 vaccine administration shall be billed with revenue code 0771 (Preventive Care Services – Vaccine Administration). Using other revenue codes may result to bundling into a case rate.
  • Report CPT codes 90460 and 90461 only when the physician or other qualified healthcare professional provides face-to-face counseling to the patient/family during the vaccine administration.
  • Code 90460 is reported once for the first component of each vaccine or toxoid administered by any route.
  • Code 90461 is additionally reported for the counseling associated with each additional component of any combination vaccine or toxoid.
  • A component refers to all antigens in a vaccine that prevents disease(s) caused by one organism. Multivalent antigens or multiple serotypes of antigens against a single organism are considered a single component of vaccines. Combination vaccines are those vaccines that contain multiple vaccine components. Conjugates or adjuvants in vaccines are not considered parts of the vaccine as defined above. See the reference table below.
  • For more related information about vaccine and administration, refer to Immunization Administration Billed with Other Services for more related information.
  • According to ACIP, effective September 22, 2023, * Maternal RSV vaccine is recommended for pregnant people during 32 through 36 weeks of gestation. Be sure to indicate the appropriate diagnosis code for the weeks of gestation. (e.g. Z3A.32, Z3A.33, Z3A.34, Z3A.35, or Z3A.36). Refer to https://www.cdc.gov/vaccines/hcp/acip-recs/ for the latest ACIP recommendation.

Components of Common Pediatric Vaccines

Vaccine Number of Vaccine Components Immunization Adminstration Codes(s) Reported
Haemophilus influenzae type b - Hib 1 90460
Human Papillomavirus Virus 1 90460
Influenza 1 90460
Meningococcal 1 90460
Pneumococcal 1 90460
Rotavirus 1 90460
Haemophilus influenzae type b / Hepatitis B - (HepB-Hib) 2 90460, 90461
Tetanus and Diphtheria (Td) 2 90460, 90461
Diphtheria, Tetanus and Pertussis (DTaP) 3 90460, 90461 x 2
Tetanus, Diphtheria, and Pertussis (Tdap) 3 90460, 90461 x 2
Haemophilus influenzae type b - Hib 1 90460
Diphtheria, Tetanus and Pertussis (DTaP) / Polio - (DTaP-IPV) 4 90460, 90461 x 3
Diphtheria, Tetanus and Pertussis (DTaP) / Polio / Haemophilus influenzae type - (DTaP-Hib) 4 90460, 90461 x 3
Measles, Mumps, Rubella and Varicella (MMRV) 4 90460, 90461 x 3
Diphtheria, Tetanus and Pertussis (DTaP) / Hepatitis B / Polio - (DTaP-HepB-IPV) 5 90460, 90461 x 4
Diphtheria, Tetanus and Pertussis (DTaP) / Polio / Haemophilus influenzae type b - (DTaP-IPV/Hib) 5 90460, 90461 x 4

• Please be sure to use the most up-to-date industry-standard procedure, revenue, and diagnosis codes from the current CPT ®′′, HCPCS Level II, and ICD-10-CM manuals, as recommended by the American Medical Association (AMA), the Centers for Medicare & Medicaid Services (CMS), and the American Hospital Association.

♣ Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently.

♦CPT, diagnosis codes and ACIP recommendations are subject to change and are used as reference examples only.


Revision History

Date Nature of Revision
08/03/2026 Migrated to new platform.